ONTARIO, CANADA – March 9th, 2015
The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks, would like to announce some recent breakthroughs in the development of new cancer treatments, and the companies that play in the field.
Chemotherapy and other key cancer treatments have so far only been effective in the elimination of cancer cells that are at the initial stages. Propanc Health Group Corp (OTC: PPCH) is a Company developing a revolutionary new drug, which in its trial stages, set to potentially provide a lasting treatment option for advanced cancer cells. It would also, if approved, prevent the re-growth of cancer cells through metastasis.
Since 2007, Propanc, an innovative biopharmaceutical company, has been working with extensive drug development and oncology and clinical experts, Professor Klaus Kutz and Dr. Julian Kenyon whose combined experience of more than 60 years in medicine has been critical in the research and development of PRP anti-cancer treatment.
By focusing on metastasis (cancer spreading) as the main and most difficult challenge to treating cancer, Propanc’s PRP is designed to ensure that malignant cancer cells cannot transfer to secondary locations and seed new tumors. Its multi-functional cancer fighting properties ensure enhanced production of the naturally occurring protein E-Cadherin to prevent metastasis, prevent the transformation of epithelial cells into mesenchymal cells through epithelial-to-mesenchymal transition (EMT), and prevents cancer cell re-growth, hence preventing the spreading of cancer to vital organs of the body. By restoring E-Cadherin levels, transition of epithelial cells to mesenchymal cells is inhibited in a process that prevents the growth of invasive cells travelling to other parts of the body through the lymphatic system or blood into surrounding tissues. PRP works by altering several critical pathways for cancer cells that otherwise lead to the growth of malignant tumors.
Since the technology behind PRP uses the body’s own natural proteolytic enzymes, there is significantly less risk of serious side effects on the body compared to current treatments. PRP’s targeted approach to killing cancer cells and preventing metastasis may be complementary, or in some cases, a preferred option to chemotherapy, which in addition to killing cancer cells, damages healthy cells in the body. With targeted cancer cell treatment, Propanc’s PRP proteolytic proenzymes can potentially be used for long-term treatment.
Dr. Kenyon and Professor Kutz believe that the cure for cancer lies not in the shrinking of tumor cancer cells but in their entire elimination to prevent regeneration. Current treatments are failing to provide a lasting solution since shrinking the tumors and leaving them in the body does not completely kill all cancer cells, therefore the treatment is only a temporary solution.
At pre-clinical stage, Propanc will initially target colorectal and pancreatic cancer tumors in a two-step process of resolving identified tumors and preventing their spread through metastasis. By seeking to test, approve, and patent PRP, Propanc aims to provide its target market with a safe and highly effective treatment that could address later stage cancers.
PRP and PRP-DCM anti-cancer treatments explore a vast, untapped market that is in dire need for safe and effective folloup-up therapies for metastitic cancer. However, Propanc’s approach to cancer treatment is still fairly new in the pharmaceuticals market and this is a factor that could have investors undervaluing the company.
Many retail Investors do not yet know the many strides oncology medicine has made in the past 2 years; it can only be described as a quantum leap. In addition to the many advances made in proenzymes, many newer treatments utilize the body’s own immune system to fight cancer cells, or immuno-oncology.
Some other interesting small companies, basically one or two steps ahead of Propanc Health Group Corp (OTC: PPCH), include: Stemline Therapeutics, Inc. (NASDAQ: STML), Verastem, Inc. (NASDAQ: VSTM), CTI BioPharma Corp. (NASDAQ: CTIC). All three of these companies are oncology-focused Biotech firms, meaning they focus on Cancer treatments using a variety of advanced sciences.
Most of these companies are clinical stage Companies; meaning they do not even have a drug to sell on the market as they’re still in development. And although these companies are still working on these “possible drugs”, they still have market values ranging from $200 Million to $300 Million.
Propanc Health Group (OTC: PPCH) is moving one step closer to these ever-so-important clinical trials with the release of their news on February 23, 2015: “Propanc Initiates Next Phase of R&D Activities,” and as such, The Wealthy Biotech Trader feels the Company has the potential to have their share price increase substantially—They’re currently only valued at $800,000 and when you compare that to $300,000,000 one can only wonder the potential.
REMEMBER: Four of the best performing IPO’s of 2014 were in the Healthcare sector, but more specifically they were Biotech or Pharma companies—that’s what was really going on while CNBC was beating their chest about overhyped IPOs like Alibaba and GoPro.
The Wealthy Biotech Trader is researching several new trade ideas which have the makings for large market moves. Active traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through our Twitter and Facebook accounts, as well as newswire.
TO GET BREAKING NEWS FROM US:
Follow us on Twitter: @Wealthy_VC
Like us on Facebook: www.facebook.com/WealthyVC
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.
The Wealthy Biotech Trader’s parent company is engaged in a month-to-month, $5,000 per month investor relations contract with Propanc Health Group (OTC: PPCH). The Wealthy Biotech Trader’s controlling parent company has also been compensated $60,000 by the company in the form of a convertible note and readers should understand that we will convert this note into common shares sell them into the market as soon as the statutory 144 hold period has lapsed.
Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.